Absci (ABSI) to Release Earnings on Thursday

Absci (NASDAQ:ABSI) is anticipated to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $1.3880 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Absci (NASDAQ:ABSI) last issued its quarterly earnings data on Tuesday, March 24th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07). The business had revenue of $0.65 million during the quarter, compared to the consensus estimate of $1.38 million. Absci had a negative return on equity of 62.33% and a negative net margin of 4,113.68%. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Trading Down 0.2%

Shares of NASDAQ:ABSI opened at $5.61 on Wednesday. The stock has a market capitalization of $872.07 million, a PE ratio of -6.60 and a beta of 2.36. Absci has a 1 year low of $2.24 and a 1 year high of $5.75. The firm has a fifty day moving average price of $3.16 and a 200 day moving average price of $3.30.

Insider Transactions at Absci

In other Absci news, insider Andreas Busch purchased 100,000 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was purchased at an average price of $2.29 per share, with a total value of $229,000.00. Following the completion of the transaction, the insider directly owned 421,446 shares of the company’s stock, valued at approximately $965,111.34. This trade represents a 31.11% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 10.49% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Creative Planning raised its position in Absci by 145.4% in the second quarter. Creative Planning now owns 46,882 shares of the company’s stock worth $120,000 after purchasing an additional 27,775 shares in the last quarter. Jain Global LLC acquired a new position in Absci in the third quarter worth about $104,000. The Manufacturers Life Insurance Company raised its position in Absci by 35.8% in the second quarter. The Manufacturers Life Insurance Company now owns 40,175 shares of the company’s stock worth $103,000 after purchasing an additional 10,585 shares in the last quarter. Brooklyn Investment Group raised its position in Absci by 13,498.1% in the third quarter. Brooklyn Investment Group now owns 21,485 shares of the company’s stock worth $65,000 after purchasing an additional 21,327 shares in the last quarter. Finally, Abel Hall LLC acquired a new position in Absci in the fourth quarter worth about $54,000. Institutional investors and hedge funds own 52.05% of the company’s stock.

Analyst Ratings Changes

ABSI has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 price objective on shares of Absci in a report on Wednesday, March 25th. Morgan Stanley cut shares of Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 price target for the company. in a report on Thursday, January 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Absci in a report on Monday, April 20th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Absci presently has a consensus rating of “Hold” and an average price target of $6.44.

About Absci

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.